Breaking News

QPharma Appoints DEA Director

By Kristin Brooks | March 19, 2014

Crusan brings extensive compliance experience

Matt Crusan has been appointed director of DEA Compliance and Services at QPharma. Mr. Crusan has served as a diversion investigator with the Drug Enforcement Administration (DEA), and brings extensive knowledge of DEA regulatory policy to QPharma’s newly established DEA compliance practice.
 
Mr. Crusan joins the company from the Pharma Compliance Group, where he served as director of regulatory affairs providing DEA compliance consulting services to manufacturers, distributors, hospitals, and retail pharmacy chains. Mr. Crusan also has experience conducting enterprise-wide DEA gap analyses and development of Suspicious Order & Monitoring (SOM) programs for drug wholesalers and manufacturers.
 
The new DEA compliance practice will include offerings including mock DEA audits and inspections, due diligence/diversion analysis, Standard Operating Procedure review, and physician risk analysis.
 
“Matt’s outstanding credentials and breadth of experience speak for themselves,” said QPharma president and chief executive officer Patrick P. Den Boer. “We are pleased to welcome him to our Professional Services team.”

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks